Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

Wasatch Global Investors, an asset management company, released its “Wasatch Small Cap Growth Strategy” third-quarter 2024 ...

Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes ...

To fuel our continued growth and advance the adoption of Inspire therapy, the Company implemented the following organizational changes: Finally, Dr. Charisse Sparks, Chief Medical Officer ...

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 4.1% of Inspire Medical Systems ...

MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Inspire Medical Systems, Inc. (NYSE ... wouldn’t be good candidates for Inspire’s device, which is designed to prevent airway collapse at the base of the tongue. The company’s recent strong ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of ...

ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes together to help sleep apnea suffers. Shares of ResMed (RMD) and Inspire ...